NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Features of Antibiotic Drug Advertisements in Medical Journals.

MORAN L, GILAD J, BORER A, MEYDAN N, SCHLAEFFER F; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. O-1012.

Soroka Univ. Med. Ctr., Beer-Sheva, Israel

BACKGROUND: Drug advertisements (DA) in medical journals (MJ) are a leading strategy for marketing of pharmaceutical products. Our aim was to assess whether DA of antibiotics (DA-AB) differed from those of other agents (DAO). METHODS: We analyzed the features of DA published in the first 3 issues of year 2000 in 24 leading MJ (total 72 issues, 779 DA). DA-AB were compared to DAO by univariate analysis. RESULTS: Of 779 DA analyzed, 194 (25%) promoted antibiotics. Compared to DAO, DA-AB were more likely to appear in pediatric MJ (40% vs 16%, p<0.001) but less in MJ of surgery and internal medicine (34% vs 48% and 13.5% vs 27%, respectively, p<0.001). There was no significant difference in the presentation of statistical analyses (7% vs 11%), tables and figures (14% vs 15%), and scientific references (56% vs 52%). DA-AB were less likely to feature a human character (29% vs 45%, p<0.001). There were no differences regarding the identity, race or gender of featured humans. Humans featured in DA-AB were more likely to show satisfaction after therapy (14% vs 2%, p=0.005) and exhibit sleepiness (5% vs 0%, p=0.01). DA-AB was less likely to contain prescribing information (80% vs 86%, p<0.03). There were no differences in the pictorials presented. DA-AB were more likely to present their product as one that fights disease strongly (25% vs 12%, p<0.001) and convenient for use (9% vs 4%, p=0.04) and less likely as one that provides solutions (2% vs 11%, p<0.001). Conclusion: There seem to be several promotional features of DA-AB that differ from those of other drugs that may possible influence AB consumption. The lack of focus on the risks of AB resistance in an era of emerging multi-resistant bacteria is most worrisome and strategies to prevent inappropriate AB consumption secondary to DA are urgently needed.

Publication Types:
  • Meeting Abstracts
Keywords:
  • 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid
  • Advertising as Topic
  • Anti-Bacterial Agents
  • Child
  • Humans
  • Penicillins
  • Periodicals
  • Pharmaceutical Preparations
  • Prescriptions, Drug
  • Publishing
  • amsonic acid
  • instrumentation
  • surgery
Other ID:
  • GWAIDS0028467
UI: 102268091

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov